Risk matrix for a highly complex nuclear medicine facility based on radiological incident analysis and follow-up

Authors

DOI:

https://doi.org/10.32685/2590-7468/invapnuclear.6.2022.649

Keywords:

risk matrix, nuclear medicine, radiological incidents, process deviations, SEVRRA

How to Cite

[1]
N. Barbosa Parada, B. E. Quiroz Revelo, Y. M. Cruz Guerra, L. Sandoval Castillo, X. Cely Segura, and F. Niño Duarte, “Risk matrix for a highly complex nuclear medicine facility based on radiological incident analysis and follow-up”, rev. investig. apl. nucl., no. 6, pp. 21–32, Jun. 2022.

Issue

Section

Articles

Published

2022-06-21

Abstract

The radiotherapy risk assessment system (SEVRRA in spanish) software and the risk matrix methodology are regional initiatives for the implementation of safety assessments in radioisotope medical and industrial facilities. In the present study, the risk matrix methodology was adapted for the practice of highly complex diagnostic nuclear medicine and radiometabolic therapy facilities. Quantitative methods were established using known exposure scenarios and calculations of the dose-effect relationship. Four years of review and follow-up of incidents showed that it was necessary to reevaluate the initial matrix and define a cyclical analysis procedure of the initiating events (IE) and its safety functions. As a result, 14 IEs were included, 25 were removed, and 28 were modified. Safety functions increased in the practice of radiometabolic therapies, while for diagnosis, they decreased. In the final risk matrix, IEs classified as high risk were not found. A remarkable decrease in those with medium risk, and an increase in those with low risk were also found. The incident report analysis allows us to conclude that the level of risk associated with the previously evaluated facility does not increase; instead, it decreases. The risk matrix must be periodically re-evaluated as the safety assurance program is implemented as a quality culture cornerstone.

References

Aplicación del método de la matriz de riesgo a la radioterapia, Organismo Internacional de Energía Atómica (OIEA), Viena, 2012.

Foro Iberoamericano de Organismos Reguladores Radiológicos y Nucleares, Sistema de Evaluación del Riesgo en Radioterapia (SEVRRA), [en línea], 2010. Disponible en: https://www.foroiberam.org/sevrra

C. Duménigo, M. Guerrero, R. López et al., “Matrices de riesgo en medicina nuclear. Modelación en SEVRRA”, en: X Congreso Regional Latinoamericano IRPA de Protección y Seguridad Radiológica, Buenos Aires, 2015.

C. Duménigo, M. Guerrero, Y. Cruz et al., “Evaluaciones de seguridad de la práctica de medicina nuclear utilizando el método de matrices de riesgo”, en: IX Latin American IRPA Regional Congress on Radiation Protection and Safety - IRPA 2013. Río de Janeiro, abril 15-19, 2013.

Ministerio de Minas y Energía, “Resolución 90874 de 2014”, Diario Oficial, n.° 49.241, pp. 59-72, 2014.

Foro Iberoamericano de Organismos Reguladores Radiológicos y Nucleares, SEVRRA RADIOTERAPIA, [en línea], 2012. Disponible en: https://www.foroiberam.org/web/guest/sevrra-radioterapia

The 2007 Recommendations of the International Commission on Radiological Protection, International Commission on Radiological Protection (ICRP), publ. 103, Ontario, Canadá, 2007.

Radiation dose to patients from radiopharmaceuticals, International Commission on Radiological Protection (ICRP), publ. 53, Ann. ICRP 18, Ontario, Canadá, 1988.

Environmental protection - The concept and use of reference animals and plants, International Commission on Radiological Protection (ICRP), pub. 108, Ann. ICRP 38(4-6), Ontario, Canadá, 2008.

J. R. Russell, M. G. Stabin, R. B. Sparks et al., “Radiation absorbed dose to the embryo/fetus from radiopharmaceuticals”, Health Physics, vol. 73, n.° 5, pp. 756-769, 1997. https://doi.org/10.1097/00004032-199711000-00003

M. W. Konijnenberg, “Is the renal dosimetry for [90 Y-DOTA 0, Tyr 3] octreotide accurate enough to predict thresholds for individual patients? Cancer Biotherapy and Radiopharmaceuticals, vol. 18, n.° 4, pp. 619-625, ago. 2003. https://doi.org/10.1089/108497803322287718

M. S. Hofman, L. Emmett, S. Sandhu et al., “[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial, The Lancet, vol. 397, n.° 10276, pp. 797-804, feb. 2021. https://doi.org/10.1016/S0140-6736(21)00237-3

J. Strosberg, G. El-Haddad, E. Wolin et al., “Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors”, The New England Journal of Medicine, vol. 376, n.° 2, pp. 125-135, ene. 2017. https://doi.org/10.1056/NEJMoa1607427

B. R. Haugen, E. K. Alexander, K. C. Bible et al., American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer, Thyroid, vol. 26, n.° 1, pp. 1-133, ene. 2016. https://doi.org/10.1089/thy.2015.0020

B. Emami, J. Lyman, A. Brown et al., “Tolerance of normal tissue to therapeutic irradiation”, International Journal of Radiation Oncology, Biology, Physics, vol. 21, n.° 1, pp. 109-122, may. 1991. https://doi.org/10.1016/0360-3016(91)90171-y

A. de los Reyes A. Llamas-Olier A. Martí et al., “Eficacia de lutecio-177 DOTATATE/TOC en pacientes con tumores neuroendocrinos bien diferenciados en estado avanzado. Ensayo clínico fase II”, Revista Colombiana de Cancerología, vol. 25, n.° 1, pp. 13-24, 2021. https://doi.org/10.35509/01239015.132

M. S. Hofman, J. Violet, R. J. Hicks et al., “[177Lu]-PSMA- 617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study”, Lancet Oncology, vol. 19, n.° 6, pp. 825-833, 2018. https://doi.org/10.1016/S1470-2045(18)30198-0

C. Kratochwil, F. L. Giesel, M. Stefanova et al., “PSMA- targeted radionuclide therapy of metastatic castration- resistant prostate cancer with 177Lu-Labeled PSMA-617”, Journal of Nuclear Medicine, vol. 57, n.° 8, pp. 1170-1176, ago. 2016. https://doi.org/10.2967/jnumed.115.171397

C. Hindorf, G. Glatting, C. Chiesa, O. Lindén, and G. Flux, “EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry”, European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 6, pp. 1238-1250, Apr. 2010. https://doi.org/10.1007/s00259-010-1422-4

G. B. Saha, Physics and Radiobiology of Nuclear Medicine, Nueva York: Springer, 2006. https://doi.org/10.1007/978-1-4614-4012-3

W. Jaschke, M. Schmuth, A. Trianni et al., “Radiation-induced skin injuries to patients: What the interventional radiologist needs to know”, CardioVascular and Interventional Radiology, vol. 40, n.° 8, pp. 1131-1140, 2017. https://doi.org/10.1007/s00270-017-1674-5

E. J. Grant, A. Brenner, H. Sugiyama et al., “Solid cancer incidence among the life span study of atomic bomb survivors: 1958-2009”, Radiation Research, vol. 187, n.° 5, pp. 513-537, may. 2017. https://doi.org/10.1667/rr14492.1

K. Gupta, C. M. Sleezer y D. F. Russ-Eft, A practical guide to needs assessment, 2.ª ed., Hoboken: Pfeiffer/ John Wiley & Sons. D. F., 2007.

K. Simon, “The cause and effect (a.k.a. fishbone) diagram”, [internet], “ISIXSIGMA.com”, Disponible en: https://www.isixsigma.com/tools-templates/cause-effect/cause-and-effect-aka-fishbone-diagram/

M. G. Stabin, Fundamentals of nuclear medicine dosimetry, Nueva York: Springer, 2008. https://doi.org/10.1007/978-0-387-74579-4

Benua R, Cicale N, Sonenberg M, Rawson R. “The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer”, American Journal of Roentgenology Radium Therapy and Nuclear Medicine, n.° 87, pp. 171-82, ene. 1962. https://doi.org/10.1001/archpedi.1962.02080020746001

Z. H. Amador, A. Torres, L. Sánchez et al., “Análisis de riesgo en la Medicina Nuclear Terapéutica en Cuba con enfoque integrador”, Revista Habanera de Ciencias Médicas, vol. 19, n.° 1, pp. 167-180, 2020. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/2850

B. Amador y V. Torres, “Análisis de riesgo radiológico en medicina nuclear terapéutica paciente específico”, Journal of Health and Medical Sciences, vol. 4, n.° 4, pp. 215-223, 2018.

Ministerio de Minas y Energía, “Resolución 181434 de 2002”, Diario Oficial, n.° 45.027, pp. 2-21.

C. Guerrero y C. Duménigo, Experiencia de la aplicación de la matriz de riesgos del medicamento nuclear en un hospital capitalino, Cuba: Centro de Protección e Higiene de las Radiaciones, 2018.

Downloads

Download data is not yet available.